文献速递脑血管病神经重症与神经感染

填补动脉瘤性蛛网膜下腔出血的证据缺口:需要务实随机试验平台

Addressing the Evidence Gap in Aneurysmal Subarachnoid Hemorrhage: The Need for a Pragmatic Randomized Trial Platform.
PubMed 文献 · Stroke · 2024-07-25

动脉瘤性蛛网膜下腔出血(aSAH)虽较其他卒中类型少见,但影响年轻患者,长期残疾负担高;随机临床试验(RCT)证据相对缺乏。本文提出建立aSAH务实随机试验平台,采用标准化入组标准、随机化流程和终点定义,以持续评估多种靶向干预,并借助贝叶斯分析框架、共享对照和适应性设计提高试验效率。

要点

  • aSAH患者年轻、长期残疾负担重,但RCT证据相对缺乏。
  • 试验平台可标准化入组、随机化和终点定义,持续纳入和退出干预。
  • 贝叶斯分析框架支持期中分析、早期终止、共享对照和适应性设计。

核心结论

  • 建立aSAH务实随机试验平台有助于缩小aSAH与其他卒中类型之间的证据缺口,并改善这一公共卫生负担沉重疾病的结局。

研究设计与样本

  • 本文为述评,提出建立aSAH务实随机试验平台的构想,未报告样本量。

主要发现

  • aSAH较其他卒中类型少见,但影响年轻患者,造成不成比例的高长期残疾负担。
  • 尽管管理进步改善了结局,但相对较少aSAH治疗在RCT中接受过检验。
  • COVID-19的经验表明,试验平台可在复杂疾病和挑战性条件下促进多中心RCT的高效执行。

关键数值与推荐

  • 平台采用标准化入组标准、随机化流程和终点定义,使多种靶向干预能以持续方式研究,治疗依据预设决策算法进入和退出平台。
  • 采用总括性机构审查委员会方案和临床试验协议,使单个治疗臂能作为修正案高效添加,而非独立方案。
  • 使用美国国立卫生研究院/国家神经疾病与卒中研究所通用数据元素的标准化病例报告表,以及跨治疗臂的方案标准化,可产生数据管理和监查的协同效应。
  • 贝叶斯分析框架强调频繁期中分析,以便因无效而早期终止治疗臂,并支持共享对照、跨臂信息借用和适应性设计。
  • 方案开发委员会将协助研究者并鼓励务实设计,以最大化普遍性、减少中心负担并高效经济地执行试验。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aneurysmal subarachnoid hemorrhage (aSAH) occurs less often than other stroke types but affects younger patients, imposing a disproportionately high burden of long-term disability. Although management advances have improved outcomes over time, relatively few aSAH treatments have been tested in randomized clinical trials (RCTs). One lesson learned from COVID-19 is that trial platforms can facilitate the efficient execution of multicenter RCTs even in complex diseases during challenging conditions. An aSAH trial platform with standardized eligibility criteria, randomization procedures, and end point definitions would enable the study of multiple targeted interventions in a perpetual manner, with treatments entering and leaving the platform based on predefined decision algorithms. An umbrella institutional review board protocol and clinical trial agreement would allow individual arms to be efficiently added as amendments rather than stand-alone protocols. Standardized case report forms using the National Institutes of Health/National Institute of Neurological Disorders and Stroke common data elements and general protocol standardization across arms would create synergies for data management and monitoring. A Bayesian analysis framework would emphasize frequent interim looks to enable early termination of trial arms for futility, common controls, borrowing of information across arms, and adaptive designs. A protocol development committee would assist investigators and encourage pragmatic designs to maximize generalizability, reduce site burden, and execute trials efficiently and cost-effectively. Despite decades of steady clinical progress in the management of aSAH, poor patient outcomes remain common, and despite the increasing availability of RCT data in other fields, it remains difficult to perform RCTs to guide more effective care for aSAH. The development of a platform for pragmatic RCTs in aSAH would help close the evidence gap between aSAH and other stroke types and improve outcomes for this important disease with its disproportionate public health burden.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Kamel H, Suarez JI, Connolly ES, et al. Addressing the Evidence Gap in Aneurysmal Subarachnoid Hemorrhage: The Need for a Pragmatic Randomized Trial Platform. Stroke. 2024. PMID: 39051124. doi:10.1161/STROKEAHA.124.048089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。